ストックスクリーナーアプリを入手
3.52
2.62%
0.09
前日終値:
$3.43
開ける：
$3.46
24時間の取引高:
1.36M
Relative Volume:
0.89
時価総額：
$237.91M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-20.51
EPS:
-0.1716
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
+10.00%
1か月 パフォーマンス:
+23.51%
6か月 パフォーマンス:
-72.15%
1年 パフォーマンス:
-26.24%
1日の値動き範囲:
$3.40
$3.75
1週間の範囲:
$3.02
$3.75
52週間の値動き範囲:
$2.70
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.52 | 237.91M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Cantor Fitzgerald Forecasts CATX FY2025 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 - The Manila Times
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Financial Survey: Beyond Air (NASDAQ:XAIR) versus Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Perspective Therapeutics provides business updates, strategic priorities - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush - MarketBeat
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics Advances Cancer Pipeline with $227.8M Cash Runway Through 2026 - StockTitan
Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Neumora Therapeutics Inc (NMRA): A New Perspective - Stocks Register
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics CEO to Present at JP Morgan Healthcare Conference and Biotech Showcase - StockTitan
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Jane Street Group LLC - Defense World
Perspective Therapeutics Appoints New Chief Financial Officer - TipRanks
Perspective Therapeutics Announces Chief Financial Officer Changes - Marketscreener.com
Perspective Therapeutics Names Juan Graham as Finance Chief - MarketWatch
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer - The Manila Times
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Geode Capital Management LLC Has $15.55 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Barclays PLC Grows Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM - Seeking Alpha
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
State Street Corp Grows Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by State Street Corp - MarketBeat
Minerva Surgical (NASDAQ:UTRS) versus Perspective Therapeutics (NYSE:CATX) Financial Contrast - Defense World
Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Neuroendocrine Tumor Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - NEWS CHANNEL NEBRASKA
Perspective Therapeutics (NYSE:CATX) vs. NeuroPace (NASDAQ:NPCE) Head to Head Contrast - Defense World
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces pivotal moment - Investing.com
BNP Paribas Financial Markets Buys 44,174 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock - MarketBeat
Janus Henderson Group PLC Has $64.01 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Fmr LLC Purchases 5,370,392 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock - Investing.com India
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock - Investing.com India
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock By Investing.com - Investing.com Nigeria
Perspective Therapeutics selloff a buying opportunity, says JonesResearch - MSN
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
3.55%
大文字化:
|
ボリューム (24 時間):